[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Pennsylvania\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":652},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,215,0,25,[9,54,78,115,144,168,191,215,251,275,302,330,350,377,402,429,449,473,495,515,540,557,590,610,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053703","de-restrict-deimplementing-activity-restriction-for-preterm-birth-prevention-100053703",false,"NCT07698483","DE-RESTRICT: Deimplementing Activity Restriction for Preterm Birth Prevention","Deimplementation of Activity Restriction for Preterm Birth Prevention in High-Risk Pregnancy (DE-RESTRICT): A Pilot Single-Arm Hybrid Effectiveness-Deimplementation Trial","Inclusion Criteria:\n\n* For Providers: Physicians, midwives, physician assistants, nurse practitioners, nurses, nursing assistants, medical assistants, and other healthcare staff who provide or participate in prenatal or high-risk pregnancy care or consultation at a participating site.\n* For Patients: Secondary patient-reported outcomes draw on pregnant individuals at high risk for preterm birth (qualifying diagnoses include short cervix, cervical insufficiency, multiple gestation, preterm labor, preterm contractions, vaginal bleeding, placental conditions, or a history of prior preterm birth), between 0 and 12 weeks postpartum for the survey measures. The activity restriction recommendation measure is collected through the Take Home Electronic Assessment (THEA) and therefore reaches only patients enrolled in THEA, at 33 weeks of gestation, across all periods; in the pre-deimplementation and post-deimplementation periods the additional survey battery is sent only to patients with a qualifying high-risk diagnosis.\n\nExclusion Criteria:\n\n* For Providers: Staff who self-exclude by choosing not to interact with deimplementation meetings and communications\n* For Patients: Patients are excluded if they are unable to walk or are hospitalized without discharge home before delivery after the qualifying diagnosis is made.",true,"ALL","18 Years",{"count":21,"type":22},237,"ESTIMATED","INTERVENTIONAL",[25],"NA","DE-RESTRICT is a pilot study testing whether a strategy to reduce the use of activity restriction and bedrest in pregnancy is acceptable, appropriate, and feasible for prenatal care providers, and whether it changes how often activity restriction is recommended. Activity restriction and bedrest are commonly advised to try to prevent preterm birth, but they do not prevent it and may cause harm, and national guidelines recommend against them. The study takes place at two prenatal care settings within one health system and unfolds across four periods. In the pre-deimplementation period the study team develops a local clinical guideline and measures baseline outcomes. In the run-in period most provider education is delivered through interactive sessions with feedback, and audit and feedback begins. In the maintenance period audit and feedback continues. In the post-deimplementation period audit and feedback continues and outcomes are measured again. The study measures provider acceptability, appropriateness, and feasibility, the rate of activity restriction recommendations, patient-reported wellbeing and care experience, and the preterm birth rate.",[28,29,30,31],"Preterm Birth","Activity Restriction","Bed Rest","Low-Value Care",[33,34,35,36,37,38,39,40],"deimplementation","low-value care","activity restriction","bedrest","preterm birth","audit and feedback","implementation science","hybrid trial","NOT_YET_RECRUITING","2026-07-07",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":22},"2026-07-01",{"date":49,"type":22},"2027-08-31",{"name":51,"class":52},"University of Pennsylvania","OTHER",2,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100509762","the-actuate-cbc-study-100509762","NCT05917652","The Actuate-CBC Study","THE Actuate-CBC Study: Accelerating the Uptake of Telemedicine for Crisis Burn Care","ACTUATE","Inclusion Criteria:\n\n* 18 years of age or older and\n* are providing burn care to patients at the 4 burn centers and the non-burnhospitals are eligible for inclusion.\n\nExclusion Criteria:\n\n* do not meet inclusion criteria,\n* decline to participate or do not give consent to participate in the study, •\n* directly express uneasiness about the participation",{"count":63,"type":22},2183,"OBSERVATIONAL","The study team will use implementation science to accelerate the uptake of teleconsultationfor burn patients by 1) examining the relationships between clinician perceptions of acceptability, feasibility, intention to use, and actual use of burn teleconsultation 2) identifying the optimal process for burn teleconsultation and the barriers and facilitators for its use during a crisis or prolonged care situation, and 3) designing and testing the effectiveness of a specific, tailored burn teleconsultation toolkit intervention to increase burn teleconsultation use.",[67],"Telemedicine","RECRUITING","2026-06-26",{"date":71,"type":45},"2026-06-29",{"date":73,"type":45},"2023-01-04",{"date":75,"type":22},"2027-06-15",{"name":51,"class":52},4,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":102,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100598472","phase-2-a-clinical-trial-of-early-ventilation-in-amyotrophic-lateral-sclerosis-event-als-100598472","NCT07071935","A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)","A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)","EVENT ALS","Inclusion Criteria:\n\n* Diagnosed with ALS using the Gold Coast Criteria within the last 6 months\n* Age ≥18 years\n* Willingness and ability to participate in study procedures\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n1. Current or prior or recommended\u002Fprescribed use of NIV including:\n\n   i) bi-level positive pressure ventilation, such as a respiratory assist device or home ventilator ii) Current or prior use of continuous positive airway pressure, or \"CPAP\" therapy\n2. Forced vital capacity \\\u003C50% of predicted normal\n3. Maximal inspiratory pressure \\> -60 cmH2O (eg, -50 or -40 cmH2O would be excluded)\n4. Chronic use of supplemental oxygen at any part of the day\n5. Enrollment in hospice\n6. Current tracheostomy\n7. Prior history of sleep apnea where non-invasive ventilation was used or recommended\n8. Thoracic, abdominal, facial or ophthalmic surgery in the prior 6 weeks\n9. Coughing up blood\n10. Myocardial infarction in the previous 4 weeks\n11. Absolute contraindication to NIV, which includes lethargy, obtundation, facial fractures, active pneumothorax, and airway obstruction (such as a tumor)\n12. Presence of cognitive dysfunction that would impair ability to complete study procedures, as determined by neurology attending physician",{"count":87,"type":22},48,[89],"PHASE2","Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS. The treatment for breathing is non-invasive ventilation (NIV). It is a machine that helps a person breathe by pushing air in and out of their lungs through a mask worn over the face. Research has shown that NIV can improve the quality of life and survival of someone with ALS. Unfortunately, NIV is not equally beneficial for everyone. The investigators do not yet know the best time or method for starting NIV in ALS. Europe and Canada allow starting NIV much earlier in ALS than the United States. Current recommendations for starting NIV are based on the opinion of experts rather than large research studies. Medical insurance companies will not cover NIV until significant breathing weakness occurs. After NIV is started, there is no evidence-based guidance on the best way to adjust NIV to benefit patients as much as possible. Some patients have difficulty tolerating NIV, but it is not clear how to identify these individuals ahead of time.\n\nThe investigators have created a new prediction tool that can identify patients at high risk of breathing problems within the next 6 months. This may help the study team identify who is more likely to benefit from starting NIV early. The investigators have published a paper that shows that NIV helps people with ALS live longer. This paper also showed that patients get more benefit with use NIV for at least 4 hours per day. The investigators published another paper that measured a gas called carbon dioxide (CO2), which goes high if someone's breathing is weakened. This paper showed that patients with ALS may live longer when CO2 levels are lowered using NIV. The investigators also have data suggesting that certain characteristics may predict who is less likely to use NIV at least 4 hours per day.\n\nIn this study, the investigators will collect pilot data on starting early NIV in individuals with ALS who do not yet meet insurance criteria for covering NIV. The research team will first use their previously published prediction tool to identify patient risk. Then, subjects would be randomized to start early NIV or to usual care. The usual care group would eventually start NIV as would occur if the participants were not in the study.\n\nThe purpose of this study is to collect data to help the investigators plan a larger randomized clinical trial. This study has 4 objectives. First, the project aims to identify individuals who would benefit from earlier NIV. The research team will use the original prediction tool to identify risk of severe breathing problems within the next 6 months. Second, the project aims to show that it is feasible to start NIV early. Third, the project aims to gather data on the effect of randomization on symptoms, CO2 levels, and outcomes. Fourth, the project aims to identify traits that may make someone less likely to use NIV.",[92,93,94,95,96,97,98,99,100,101],"Amyotrophic Lateral Sclerosis (ALS)","Chronic Respiratory Failure","Neuromuscular Disease Patients","Neuromuscular Disease","Respiratory Insufficiency","Respiratory Insufficiency Requiring Mechanical Ventilation","Positive Pressure Ventilation","Non-invasive Ventilation","Non-invasive Ventilation Support","Non-invasive Ventilatory Support",[103,104,105,106],"chronic respiratory failure","chronic neuromuscular respiratory failure","non-invasive ventilation","amyotrophic lateral sclerosis","2026-06-25",{"date":69,"type":45},{"date":110,"type":45},"2026-06-11",{"date":112,"type":22},"2029-05",{"name":51,"class":52},3,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":17,"sex":123,"minAge":19,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100632840","protecting-against-lenacapavir-misinformation-with-young-women-in-gauteng-south-africa--protect-l-100632840","NCT07518914","Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)","Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa","PROTECT-L","Inclusion Criteria:\n\n* Female (cisgender or transgender)\n* Age 18-29 years\n* Self-reported history of sexual activity in the past 12 months\n* Self-reported HIV-negative status or unknown HIV status at enrolment\n* Willing and able to provide consent\n* Able to read and understand English\n\nExclusion Criteria:\n\nUnwilling or unable to provide consent for study participation.","FEMALE","29 Years",{"count":126,"type":22},1500,[25],"Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. However, LEN's potential may be undermined by misinformation, particularly around safety and trust, which has been shown in other HIV prevention contexts to reduce uptake and demand. Proactive strategies, such as psychological inoculation, are therefore needed to prebunk misinformation and support future LEN implementation among AGYW.\n\nPrimary objective: To compare changes in intentions to receive Lenacapavir following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.\n\nSecondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about Lenacapavir in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.",[130,131],"Misinformation","Lenacapavir",[133,131,134,135],"South Africa","Adolescent Girls and Young WOmen","PrEP","2026-06-24",{"date":69,"type":45},{"date":139,"type":45},"2026-05-19",{"date":141,"type":22},"2029-04",{"name":51,"class":52},1,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100473544","the-diaphragmatic-initiated-ventilatory-assist-diva-trial-100473544","NCT05446272","The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial","DIVA","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7- 28 6\u002F7 weeks at birth\n* Intubated in the first 7 days of life\n* Undergoing extubation following at least 12 hours of invasive mechanical ventilation\n* Post-natal age \\\u003C32 weeks Post menstrual age at time of extubation\n\nExclusion Criteria:\n\n* Major congenital anomalies, including pulmonary hypoplasia\n* Neurologic disorders affecting respiratory drive (other than apnea of prematurity)\n* Esophageal bleeding or other contraindication to NG\u002FOG catheter placement\n* Current weight \\\u003C500 grams (based on Edi catheter approval)\n* Study ventilator not available at time eligibility criteria are met\n* Planned surgery or invasive procedure within 5 days of extubation\n* Informed consent not provided","0 Days","9 Weeks",{"count":154,"type":22},478,[25],"DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0\u002F7-28 6\u002F7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.",[158,159,160],"Extubation Failure","Bronchopulmonary Dysplasia","Death",{"date":107,"type":45},{"date":163,"type":45},"2022-08-03",{"date":165,"type":22},"2027-12-31",{"name":51,"class":52},20,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":17,"sex":18,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":143},"100644591","intervention-to-improve-parent-communication-about-sexuality-100644591","NCT07672067","Intervention to Improve Parent Communication About Sexuality","Youth participants (1) identify as a cisgender sexual minority male (e.g., gay, bisexual or queer) who has disclosed sexual orientation to parent or trusted caregiver (2) be aged 14-18 years; (3) able to comprehend spoken English; (4) resides in the United States; (5) consents or assents to study participation\n\nParent participants (1) parent, legal guardians, legal custodians (hereinafter \"parent\") of GBQ adolescent; (2) age 18 or older; (3) able to comprehend spoken English; (4) resides in the United States; (5) knows their GBQ child's sexual orientation (6) consents to study participation; and (7) consents to their GBQ child's study participation.","14 Years","100 Years",{"count":177,"type":22},476,[25],"The study is centered on helping parents answer and meet the sexuality-specific questions and needs of gay or bisexual males. This study seeks to test the efficacy of Parents ASSIST as a parent-child sexuality communication intervention that educates and trains parents to be purveyors of inclusive health information as gay or bisexual sons come of age at home.",[181,182,183],"Sexual Health","HIV\u002FSTI","Family Communication","2026-06-22",{"date":69,"type":45},{"date":187,"type":45},"2026-05-01",{"date":189,"type":22},"2029-08-30",{"name":51,"class":52},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":53},"100466885","how-hormones-and-exposure-and-response-prevention-exrp-affect-the-brain-of-people-with-ocd-100466885","NCT05359562","How Hormones and Exposure and Response Prevention (EX\u002FRP) Affect the Brain of People With OCD","Harnessing Hormonal Variation to Probe Neural Mechanisms and Optimize CBT Outcomes for OCD","Inclusion Criteria:\n\n1. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Diagnosis of OCD;\n2. Male and female subjects aged between 18- 45;\n3. Women must be menstruating and regularly cycling\n4. Ability to tolerate a treatment-free period;\n5. No psychotropic medication in the past 12 weeks\n6. At entry, at least moderate severity OCD\n7. Willingness and ability to give written informed consent after full explanation of study procedures.\n\nExclusion Criteria:\n\n1. Use of birth control (oral contraception or IUD) that affects the menstrual cycle, or menopause.\n2. Pregnancy. Women of childbearing potential will be required to sign a statement indicating their intention to avoid pregnancy during the study.\n3. Neurologic or medical condition that would prevent safe participation in the full study protocol.\n4. Any contradiction to magnetic resonance imaging (e.g., metallic implants or devices).\n5. Comorbid psychiatric conditions that significantly elevate the risks associated with study participation or confound results.\n6. Patients with prominent suicidal ideation or with a recent suicide attempt.\n7. Current psychotherapy","45 Years",{"count":200,"type":22},120,[25],"Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX\u002FRP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX\u002FRP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms.",[204],"OCD",[204,206,207],"Exposure and Ritual Prevention","Extinction Learning","2026-06-17",{"date":184,"type":45},{"date":211,"type":45},"2022-06-15",{"date":213,"type":22},"2028-06-30",{"name":51,"class":52},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":235,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":143},"100642005","reward-sensitivity-digital-intervention-for-suicide-risk-100642005","NCT07661901","Reward Sensitivity Digital Intervention for Suicide Risk","Pilot Development of a Youth-Focused Digital Just-in-Time Adaptive Intervention to Enhance Reward Sensitivity and Reduce Suicidal Ideation","DIGIReward","Inclusion Criteria:\n\nADOLESCENTS\n\n* Aged 13-17 years old\n* Recent suicidal ideation\n* Access to a smartphone device\n* Residing in the Philadelphia metropolitan area\n\nLEGALGUARDIANS\n\n* They are the legal guardian of an adolescent that meets all study criteria (see above)\n* They can read, write, and speak English\n\nExclusion Criteria:\n\nADOLESCENTS\n\n* Psychotic disorder, including schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified, with a past year psychotic episode prior to baseline\n* Bipolar disorder I diagnosis, with a past year manic episode prior to baseline\n* Imminent suicide risk (e.g., active suicidal ideation with a specific plan and intent)\n\nLEGALGUARDIANS\n\n\\- There are no exclusion criteria for legal guardians","13 Years","17 Years",{"count":167,"type":22},[25],"The goal of this clinical trial is to develop and test an app designed to reduce suicide risk and improve emotional well-being in adolescents. The study will test if the app's daily check ins and recommended mood boosting skills will improve the adolescent's overall mood and suicidality. The main question it aims to answer is:\n\n• Is the app practical and acceptable to use daily?\n\nIn the study, adolescents will:\n\n* Participate in a focus group with other adolescents and provide feedback on the app itself (design, ease of use, etc.).\n* Complete surveys and assessments on their mood, thoughts, and experiences.\n* Complete assessments about their app experience.\n\nIn the study, the legal guardian of the adolescent will:\n\n* Participate in a focus group with other adolescents and provide feedback on the app itself (design, ease of use, etc.).\n* Complete assessments about their app experience.",[229,230,231,232,233,234],"Suicidal Ideation","Suicidal","Suicidal Thoughts","Digital Health Intervention","Reward Sensitivity","Anhedonia",[236,237,238,239,240,241,242,243,233,234],"Adolescents","Legal Guardians","Digital","Philadelphia","Suicide","Intervention","Prevention","Dyads","2026-06-16",{"date":184,"type":45},{"date":247,"type":22},"2026-06",{"date":249,"type":22},"2027-09",{"name":51,"class":52},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":143},"100641367","phase-1-211at-mabg-in-adults-with-advanced-neuroendocrine-cancers-100641367","NCT07661420","211At-MABG in Adults With Advanced Neuroendocrine Cancers","Inclusion Criteria:\n\n1. Adult patients, at least 18 years of age\n2. Advanced neuroendocrine cancers requiring systemic therapy and refractory to, ineligible for, declining, or lacking standard treatments.\n3. I MIBG imaging indicating MIBG-avid disease (radiotracer uptake above background in at least one tumor site) per Investigator\u002FSub-Investigator assessment.\n4. Participants must provide written informed consent prior to study-specific procedures.\n5. ECOG performance status ≤ 2.\n6. Adequate organ function including:\n\n   1. Hemoglobin ≥ 9 g\u002FdL\n   2. Absolute neutrophil count ≥ 1,500\u002Fmm³\n   3. Platelet count ≥ 75,000\u002Fmm³\n   4. Measured or estimated GFR ≥ 60 mL\u002Fmin\n   5. Serum bilirubin ≤ 1.5x upper limit of normal\n   6. ALT\u002FAST each ≤ 2.5x upper limit of normal\n7. Life expectancy at least 3 months as judged by treating physician\n\nExclusion Criteria:\n\n1. Women who are pregnant or breast-feeding will not be eligible for this study.\n2. Inability to tolerate study procedures in the opinion of the investigator or treating physician.\n3. Serious or unstable medical, psychological, or social conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.\n4. Uncontrolled brain metastasis (Participant must be at least 4 weeks since CNS-directed therapy and no longer requiring corticosteroid therapy).\n5. Anticancer therapy, except hormonal therapy or bone supportive therapies, within 14 days of cycle 1 day 1.\n6. Has a known additional malignancy (other than the disease under study) that has required active systemic treatment within the past 2 years AND for which the natural history or recent\u002Fongoing treatment could likely interfere with study endpoints or safety of the study treatment per Investigator and Medical Director assessment.",{"count":258,"type":22},16,[260],"PHASE1","Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma \u002F paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).",[263,264,265,266,267,268],"Pheochromocytoma","Paraganglioma","Neuroendocrine Tumors","Medullary Thyroid Cancer","Bronchial Carcinoid","Gastroenteropancreatic Neuroendocrine Neoplasm",{"date":184,"type":45},{"date":271,"type":22},"2026-08-01",{"date":273,"type":22},"2032-08-01",{"name":51,"class":52},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":143},"100601865","phase-1-mov19-bbz-car-t-cells-in-fra-cancers-100601865","NCT07116057","MOv19-BBz CAR T Cells in FRa+ Cancers","Phase I Clinical Trial of Autologous Folate Receptor-Alpha Redirected T Cells in Patients With FRa+ Cancers","Inclusion Criteria:\n\n1. Signed informed consent form\n2. Documentation of tumor FRa expression by IHC at the Hospital of the University of Pennsylvania (≥ 10% of tumor cells). Subjects must have archived tumor tissue available.\n3. Disease-specific criteria:\n\n   a. NSCLC Patients: i. Metastatic or recurrent lung adenocarcinoma with cytologically or pathologically confirmed malignant pleural effusion.\n\n   ii. Failure of at least one prior line of standard of care therapy for advanced stage disease.\n4. Patients must have evidence of active disease as defined by RECIST 1.1 criteria\n5. Patients with asymptomatic CNS metastases that have been treated (and are off steroids for the treatment of CNS disease) are allowed. They must meet the following criteria\n\n   1. No concurrent treatment for the CNS disease\n   2. No progression of CNS metastasis on MRI at screening\n   3. No evidence of leptomeningeal disease or cord compression\n6. Adequate organ function defined as:\n\n   1. Serum creatinine ≤ 1.5 mg\u002Fdl or creatinine clearance ≥ 30 cc\u002Fmin; Patient must not be on dialysis\n   2. ALT\u002FAST ≤ 3x upper limit of normal range\n   3. Serum total bilirubin ≤ 1.5 mg\u002Fdl, unless the subject has Gilbert's syndrome (if so, serum total bilirubin must be ≤ 3.0 mg\u002Fdl)\n   4. Must have a minimum level of pulmonary reserve defined as \\\u003C Grade 1 dyspnea and pulse oxygen \\> 92% on room air\n   5. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO or MUGA\n7. Male or female age ≥ 18 years\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status that is either 0 or 1\n9. Subjects must be a possible clinical candidate for standard of care treatment with a commercial checkpoint inhibitor, as per physician-investigator assessment.\n\nExclusion Criteria:\n\n1. Any clinically significant pleural effusion that cannot be drained with standard approaches.\n2. Patients with significant lung disease as follows:\n\n   1. Patients with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and\u002For evidence of extensive bilateral parenchymal metastatic burden.Note: \"Greater than lobar\" = \"in more than 1 lobe\".\n   2. Patients with radiographic and\u002For clinical evidence of active radiation pneumonitis.\n   3. Patients with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc.).\n   4. Patients with radiographic evidence of significant pleural effusion that is not readily amenable to minimally invasive drainage.\n3. Active hepatitis B or hepatitis C infection\n4. Any other active, uncontrolled infection\n5. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification\n6. Active invasive cancer, other than the proposed cancer included in this protocol, within 2 years prior to eligibility confirmation by a physician-investigator. \\[Note: non-invasive cancers treated with curative intent (e.g., non-melanoma skin cancer) may still be eligible\\].\n7. Dependence on systemic steroids or immunosuppressant medications.\n8. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods\n9. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone daily. Patients with autoimmune neurologic diseases (such as MS) will be excluded.\n10. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)",{"count":283,"type":22},10,[260],"This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment with commercial checkpoint inhibitors per routine care beginning at least 28 days after receiving MOv19-BBz CAR T cells.",[287,288],"Metastatic Non Small Cell Lung Cancer","Recurrent Lung Non-Small Cell Carcinoma",[290,291,292,293,294],"NSCLC","CAR T cells","FRa+","lung cancer","lung adenocarcinoma",{"date":296,"type":45},"2026-06-18",{"date":298,"type":45},"2025-10-07",{"date":300,"type":22},"2040-10",{"name":51,"class":52},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":312,"briefSummary":313,"conditions":314,"keywords":318,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":143},"100590534","phase-2-transcranial-magnetic-stimulation--language-therapy-to-treat-subacute-aphasia-100590534","NCT06968663","Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia","Electrical Field Guided Transcranial Magnetic Stimulation to Treat Subacute Post-stroke Aphasia","Inclusion Criteria:\n\n* Left hemisphere stroke resulting in aphasia\n* The stroke must have occurred between 2 and 6 weeks prior to enrollment\n* Must be able to understand the nature of the study, and give informed consent\n* English proficiency\n* Right-handed\n\nExclusion Criteria:\n\n* History of serious and\u002For ongoing issues with substance abuse\n* Previous head trauma with loss of consciousness for more than 5 minutes\n* History of major psychiatric illness\n* Dementia, or other neurological conditions\n* Epilepsy, or seizure after the stroke event\n* Pacemaker\n* Diagnosis of tinnitus\n* Pregnancy","85 Years",{"count":311,"type":22},63,[89],"The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with modified Constraint Induced Language Therapy (mCILT) is an effective treatment for aphasia when delivered in the subacute stage after stroke.\n\nThe main questions this study aims to answer are:\n\n1. Can TMS combined with mCILT improve overall speech?\n2. Can we identify specific behavioral and biological characteristics that would benefit most from the TMS and mCILT treatment?\n\nResearchers will compare real TMS to sham (fake) TMS to see whether TMS can treat subacute aphasia.\n\nImportantly, this trial will use electric field guided TMS to identify optimal and individualized stimulation intensity and site targeting.\n\nParticipants will:\n\n* Complete a screening and medical intake to determine eligibility\n* Undergo MRI scans\n* Participate in 10 consecutive sessions (Monday-Friday) of TMS and mCILT treatment\n* Complete follow-up assessments immediately and 4 months after treatment",[315,316,317],"Stroke","Aphasia","Aphasia Following Cerebral Infarction",[319,320,321,322,323],"aphasia","stroke","Transcranial Magnetic Stimulation","Non-invasive brain stimulation","language therapy",{"date":296,"type":45},{"date":326,"type":45},"2024-08-01",{"date":328,"type":22},"2029-07-31",{"name":51,"class":52},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":18,"minAge":338,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":143},"100588135","traumatic-hemothorax-drainage-and-daily-lavage-100588135","NCT06937450","Traumatic Hemothorax Drainage and Daily Lavage","Traumatic Hemothorax Treatment With 14-Fr Pigtail Catheters or Large Bore (~28Fr) Chest Tubes With Daily Irrigation: A Pilot Single-Arm Intervention Study","HTXDLYLAVGE","Inclusion Criteria:\n\n1. Able to provide consent for the research study\n2. More than 15 years of age\n3. Presence of acute traumatic HTX or HTX-PTX diagnosed on chest CT scan within 24 hours of injury and clinical indication for drainage (hemothorax of moderate or large size greater then 300 mL)\n4. Hemodynamic stability (heart rate 120 beats per minute; systolic blood pressure 90 mmHg)\n5. Bilateral or unilateral hemothorax of greater than 300 mL HTX by Mergo Formula from chest CT\n6. Able to complete the entire study including randomization, tube placement, lavages and final CT Scan.\n\nExclusion Criteria:\n\n1. Less than 15 years of Age\n2. Prisoner\n3. Pregnant due to the risk of CT scans\n4. HTX or HTX-PTX not requiring drainage or drainage performed prior to randomization\u002Fenrollment\n5. Patients undergoing operative intervention (i.e. thoracotomy) as initial management of hemothorax (6) Persistent hemodynamic instability after initial resuscitation and CT imaging","15 Years",{"count":167,"type":22},[25],"This HTX treatment study evaluates the effects of chest tube size and the benefits of daily irrigations on acute HTX. 20 acutely injured but stable trauma patients requiring a chest tube for HTX will be enrolled. Patients will be assigned a 28Fr or 14 Fr chest tube with serial lavage and drainage. The endpoints will be HTX volume (by CT scan), complications, additional interventions, hospital length of stay, chest tube duration, provider feedback, and patient-reported outcomes.",[343],"Hemothorax; Traumatic",{"date":296,"type":45},{"date":346,"type":45},"2025-03-30",{"date":348,"type":22},"2027-08-01",{"name":51,"class":52},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":358,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":374,"leadSponsor":376,"locationsCount":143},"100578178","phase-2-effects-of-ketones-on-brain-energetics-and-alcohol-consumption-in-alcohol-use-disorder-100578178","NCT06807918","Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder","Effects of Ketone Supplementation on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder","KABA","Inclusion Criteria:\n\n1. Age 21-65 years old\n2. Able to provide written informed consent\n3. Meets current DSM-5 criteria for mild to moderate (established using MINI)\n4. Average weekly alcohol consumption of at least 15 standard drinks over the past month before consent (self-report)\n5. Not seeking treatment for AUD (self-report)\n\nExclusion Criteria:\n\n1. Unwilling or unable to refrain from use of alcohol, within 24 hours of Alcohol Bar Lab, MRI and PET procedures (self-report, breathalyzer).\n2. Use of psychoactive medications or medications that may affect study results (self-report, medical history).\n3. Current DSM-5 diagnosis of a major psychiatric disorder (other than alcohol, Marijuana, and nicotine use disorders) that required hospitalization or daily medication in the past year.\n4. Current significant alcohol withdrawal symptoms in the past 12 months that required medical treatment (self-report, medical history).\n5. A current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation that could interfere with study participation or make it hazardous for the subject to do so (e.g., bleeding disorder, pancreatitis, epilepsy, liver disease, kidney disease, or diabetes as determined by history and clinical exam); ALAT or ASAT concentration greater than 3 times the upper limit of normal (ULN), or bilirubin above the ULN. (Note-abnormal laboratory tests during screening may be repeated once).\n6. Current, major gastrointestinal (GI) diseases, such as: GERD, Crohn's disease, Irritable bowel syndrome, Ulcerative colitis, Celiac disease Diverticulitis, or other clinically significant physical disease that may interfere with the intake of the Ketone Supplement based on medical history, and evaluation of the Study Physician.\n7. Clinically significant laboratory findings that could affect brain function (e.g., HIV+).\n8. Head trauma with loss of consciousness for more than 30 minutes (self-report, medical history).\n9. Pregnant or breast-feeding\n10. Weight greater than 250lbs (Need to cap amount of alcohol give based on weight to individuals).\n11. BMI greater than 35.\n12. Self-reported claustrophobia.\n13. Contraindications to MRI (e.g., metal in the body that cannot be removed and is not MRI compatible).","21 Years","65 Years",{"count":361,"type":22},60,[89,363],"PHASE3","This is a randomized, double-blind, crossover trial to evaluate the immediate effects of a nutritional ketone supplement, Kenotic compared to placebo on brain function and alcohol consumption in individuals with alcohol use disorder. Participants will complete 2 MRI scans, 2 FDG PET\u002FCT scans, and 2 alcohol bar labs and will randomly receive Kenetik at one lab and the placebo at the next lab. During the bar labs participants will consume a dose of alcohol (based on weight), to bring their breath alcohol concentration to about 0.050%.",[366,367],"Alcohol Use Disorder","Ketosis",[366,367,369,370],"Ketone supplement","Magnetic Resonance Spectroscopy",{"date":372,"type":45},"2026-06-15",{"date":271,"type":22},{"date":375,"type":22},"2030-01-01",{"name":51,"class":52},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":123,"minAge":19,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":387,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":143},"100618653","early-general-anesthesia-to-limit-experiences-of-trauma-during-cesarean-section-pilot-study-100618653","NCT07334418","Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study","EAGLET-CS Pilot: Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study","EAGLET-CS","Inclusion Criteria:\n\n* Women aged 18 or older undergoing non-emergent cesarean delivery with primary neuraxial (epidural, spinal, or CSE) anesthesia. Eligible patients will be those who report severe pain during surgery, defined as pain that does not resolve with 2 trials of first-line pharmacologic therapies (e.g., epidural supplementation with local anesthetics; intravenous opioid analgesics).\n\nExclusion Criteria:\n\n* We will exclude patients who require induction of general anesthesia prior to umbilical cord clamping and by clinician determination.",{"count":386,"type":22},600,[25],"Some patients who undergo cesarean section under spinal or epidural anesthesia can experience severe pain. Some patients who experience this kind of pain can experience symptoms of post-traumatic stress disorder (PTSD) after pregnancy. Currently, the two main options for treating this pain are general anesthesia (full medically induced unconsciousness) and using intravenous medications to reduce the pain and decrease anxiety. The EAGLET-CS Pilot is a pilot randomized trial that will test the feasibility of comparing the impact of these two options for preventing PTSD in a rigorous way for those patients who experience pain during their cesarean section after the baby is out.",[390,391],"Cesarean Section","Delivery; Trauma",[390,391,393,394],"C-section","PTSD","2026-06-09",{"date":110,"type":45},{"date":398,"type":45},"2026-04-06",{"date":400,"type":22},"2027-11",{"name":51,"class":52},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":358,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":143},"100602558","lung-injury-is-one-of-the-primary-causes-of-morbidity-and-mortality-in-critically-ill-patients-these-patients-will-be-monitored-for-1-immune-cell-activation-2-blood-based-biomarkers-in-vitro-models-derived-from-these-samples-will-be-treated-with-novel-agent-pip-2-to-evaluate-its-efficacy-100602558","NCT07125079","Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.","Blood-based Biomarkers of Acute Lung Injury\u002FAcute Respiratory Distress Syndrome","ALI\u002FARDS","Inclusion Criteria: ARDS patients with mild and moderate to severe ARDS. This will be based on PaO2\u002FFiO2 in the range of 100 mmHg (severe) and moderate (100-200 mm Hg) and mild (200-300 mm Hg) -\n\nExclusion Criteria: Pregnant women, children will be excluded.\n\n\\-","90 Years",{"count":412,"type":22},36,"Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune cells and that blockade of this activation may reduce lung damage\u002Finjury and help in ARDS management and possibly recovery. To test this hypothesis, the investigators propose to generate an in vitro immune cell model and test a novel (reactive oxygen species) blocking agent PIP-2 on this model. The investigating team will obtain blood of ARDS patients and isolate immune cells (specifically peripheral blood mononuclear cells or PBMC) and monitor the activation of these cells and their blockade by PIP-2. This is entirely an in vitro study.",[415],"ARDS (Acute Respiratory Distress Syndrome)",[417,418,419,420,421],"ROS","ARDS","PIP-2","immune cells","peripheral blood mononuclear cells",{"date":423,"type":45},"2026-06-10",{"date":425,"type":45},"2025-05-20",{"date":427,"type":22},"2027-11-20",{"name":51,"class":52},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":23,"phases":437,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":448,"locationsCount":143},"100559342","patient-navigation-to-improve-surgical-access-in-primary-hyperparathyroidism-100559342","NCT06562881","Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism","Inclusion Criteria:\n\n* Diagnosed with PHPT and not yet had parathyroidectomy who meet criteria for surgical treatment of PHPT (osteoporosis, fragility fracture, or evidence of vertebral compression fracture on spine imaging, renal involvement \\[renal stone, silent nephrolithiasis on renal imaging, nephrocalcinosis, hypercalciuria (24-hour urine calcium level 400 mg\u002FdL) with increased stone risk, or impaired renal function (glomerular filtration rate 60 mL\u002Fmin)\\], calcium 1 mg\u002FdL above upper limit of normal, age less than 50)\n* Qualify as a member of a racial or ethnic minority group (Black, Hispanic, Asian and Pacific Islander, Native American), lower socioeconomic neighborhoods (by zipcode), socially vulnerable (social determinants of health indicating financial strain, social vulnerability index in the top quartile 75%+ by zip code), or with underinsurance (Medicaid, Medicare, dual eligible, uninsured)\n\nExclusion Criteria:\n\n* Prior Parathyroidectomy\n* End-stage Renal Disease\n* Renal Transplant\n* Vitamin D Deficiency\n* Metastatic Disease\n* Familial Hypocalciuric Hypercalcemia\n* No Indication for Surgery\n* Unable\u002FUnwilling to provide consent",{"count":436,"type":22},76,[25],"The goal of this study is to address surgical health equity in historically marginalized participants with primary hyperparathyroidism (PHPT). The main questions that this study aims to answer are, how does patient navigation impact:\n\n* The proportion of PHPT participants undergo parathyroidectomy?\n* The proportion of PHPT participants who complete surgical consultation?\n* Time to surgical consultation?\n* Time to surgery?",[440],"Hyperparathyroidism, Primary",[442,443],"Parathyroidectomy","Barriers and Challenges to Surgical Health Equity",{"date":110,"type":45},{"date":47,"type":22},{"date":447,"type":22},"2026-12-30",{"name":51,"class":52},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":143},"100642449","early-phase-1-18f-ftha-imaging-of-the-intestinal-and-central-lymphatic-system-100642449","NCT07645573","18F-FTHA IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","INVESTIGATION OF A POSITRON-EMITTING LONG-CHAIN FATTY ACID (18F-FTHA), FOR IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","FTHA","Inclusion Criteria:\n\nInclusion Criteria (Healthy Volunteer Cohort)\n\n1. Male and female participants will be ≥ 18 years of age.\n2. \"Healthy Volunteer\" is defined for the purposes of this study as a volunteer who is in good general health in the opinion of an investigator (some well controlled chronic medical conditions may be allowed at the discretion of an investigator if they do not believe they will interfere with the collection of imaging data, specific excluded medical conditions are listed under exclusion criteria).\n3. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nInclusion (Patient with suspected TD-venous junction obstruction cohort)\n\n1. Male and female participants will be ≥ 18 years of age\n2. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n3. Patient with chronic abdominal pain, ascites protein losing enteropathy, as well edema, with clinically suspected obstruction of the TD-venous junction and who are candidates for TD-venous junction plasty and or TD-Venous bypass\n\nExclusion Criteria:\n\nExclusion Criteria that apply to Healthy Volunteers only\n\n1. Currently taking medication for cardiac disease, hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, and\u002For history of cardiac surgery per medical record review and\u002For self-report\n2. Known history of liver or kidney disease per medical record review and\u002For self-report\n\nExclusion Criteria that applies to Healthy Volunteers and Patients:\n\n1. Women who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential on the day of each of the PET\u002FCT scans.\n2. Subjects who report claustrophobia or Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n3. Self-reported difficulty with swallowing pills or allergy to components of Ensure Plus\n4. Patients with a history of medical illness or disorder that in the opinion of an investigator and\u002For study physician could compromise patient safety or interfere with the collection of imaging data, or ability to complete the study and procedures, will be excluded.\n\nParticipant may not be involved in any other research studies involving ionizing radiation conducted within 1 year of their participation of this study.",{"count":7,"type":22},[459],"EARLY_PHASE1","The project will be performed over a period of approximately two years. In the first year the \\[18F\\]FTHA tracer will be developed, optimized, and tested on normal volunteers. During the second year, the tracer will be investigated on patients with suspected obstruction of the thoracic duct (TD).",[462],"Lymphatic Obstruction",[464],"thoracic duct","2026-06-08",{"date":467,"type":45},"2026-06-12",{"date":469,"type":45},"2025-10-10",{"date":471,"type":22},"2029-06-30",{"name":51,"class":52},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":143},"100627624","phase-1-cd45be-hspc--cart-45-cells-100627624","NCT07451054","CD45BE-HSPC + CART-45 Cells","Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n1\\. Signed informed consent form 2. Male or females age ≥ 18 years 3. Disease-Specific Criteria\n\na. B-cell Non-Hodgkin Lymphoma (B-cell NHL)- including the following sub-types:\n\ni. Patients with any of the following large B-cell lymphoma diagnoses who meet the prior treatment criteria outlined below: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS); Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements (i.e., \"Double or Triple Hit\"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.\n\n1\\. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND 2. Relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy.\n\nii. Follicular Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy (not including a single agent monoclonal antibody therapy).\n\niii. Mantle Cell Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   iv. Marginal Zone Lymphoma- relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Note: Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   b. T-cell Non-Hodgkin Lymphoma (T-cell NHL)\n\n   i. Histologically or cytologically confirmed relapsed or refractory (r\u002Fr) mature aggressive T- and NK-cell neoplasms as defined in the 5th edition of the WHO Classification of Hematolymphoid tumors, which includes any of the following diagnoses:\n\n   • Peripheral T-cell Lymphoma, NOS (PTCL-NOS);\n\n   • Nodal T-cell Lymphomas with T Follicular Helper \\[TFH\\] Phenotype, including Follicular T cell Lymphoma, Angioimmunoblastic Lymphoma, or Anaplastic Large Cell Lymphoma (ALCL);\n\n   • ALK+ or ALK-, Enteropathy-Associated T-cell Lymphoma (EATL);\n\n   • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL);\n\n   • Extranodal NK\u002FT-cell Lymphoma;\n\n   • Primary Cutaneous T-cell Lymphoma (CTCL);\n\n   • Transformed Mycosis Fungoides (tMF) without blood involvement;\n\n   • Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma;\n\n   • Subcutaneous Panniculitis-like T-cell Lymphoma.\n\n   ii. Must have received at least one prior line of systemic therapy for their lymphoma. Additional prior treatment provisions required for the following indications:\n\n1\\. Participants with Anaplastic Large Cell Lymphoma (ALCL) must have received prior Brentuximab vedotin, unless contraindicated.\n\n2\\. Participants with Subcutaneous Panniculitis-like T-cell Lymphoma or Transformed Mycosis Fungoides (tMF) must have received at least 2 prior lines of systemic therapy.\n\nc. Hodgkin Lymphoma (HL)\n\ni. Patients with histologically proven classical Hodgkin Lymphoma that is CD45 positive by IHC or flow cytometry by a CLIA certified laboratory; AND\n\nii. Relapsed\u002Frefractory disease after at least 2 prior lines of therapy which must include the following:\n\n1. Brentuximab vedotin and immune checkpoint inhibitors (unless contraindicated); AND\n2. Autologous stem cell transplant (unless patient has chemorefractory disease to salvage treatment) d. Large Cell Transformation of CLL (Richter's Transformation) i. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.\n\n4\\. Patients are appropriate candidates for autologous HSCT as per physician-investigator clinical discretion\n\n5\\. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:\n\na. Have no active GVHD and require no immunosuppression\n\nb. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility\n\n6\\. Adequate organ function defined as:\n\n1. Serum creatinine ≤ 1.5x ULN or estimated creatinine clearance ≥ 35 mL\u002Fmin and not on dialysis\n2. ALT\u002FAST ≤ 3 x ULN\n3. Direct bilirubin ≤ 2.0 mg\u002Fdl; for patients with Gilbert's syndrome direct bilirubin must be ≤ 3.0 mg\u002Fdl\n4. Left Ventricular Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO\u002FMUGA\n5. DLCO \\> 45% predicted value; adjusted for level of hemoglobin\n6. Must have minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \\> 92% on room air 7. ECOG Performance Status 0-1\n\nExclusion Criteria:\n\n1. Active hepatitis B or hepatitis C infection\n2. Any active, uncontrolled infection.\n3. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n4. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.\n5. Severe, active co-morbidity that, in the opinion of the physician-investigator, would preclude participation in this study.\n6. Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n7. Active acute or chronic GVHD requiring systemic therapy.\n8. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.\n9. Active CNS involvement. Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs\u002Fsymptoms of CNS involvement.\n10. Patients with evidence of a circulating T-cell malignancy as measured by flow cytometry.\n11. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\n12. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.\n13. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods.",{"count":481,"type":22},42,[260],"This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as \"CART-45 cells\") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as \"CD45BE-HSPC\") in patients with relapsed or refractory hematologic malignancies.",[485,486,487,488],"B-Cell Non-Hodgkin Lymphoma (NHL)","Richter's Transformation","T-Cell Non-Hodgkin Lymphoma","Hodgkin Lymphoma",{"date":423,"type":45},{"date":491,"type":22},"2026-07",{"date":493,"type":22},"2051-07",{"name":51,"class":52},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":143},"100608300","phase-2-maintenance-combinatorial-myeloid-immunotherapy-for-unresectable-pancreatic-cancer-100608300","NCT07199764","Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma","IGNITE","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients must be able to understand the study procedures and agree to participate in the study by providing written informed consent\n* Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma that is either locally advanced and unresectable, or metastatic\n* Have received a minimum of 16 and no more than 32 weeks of a first line chemotherapy-based standard of care regimen, resulting in either a PR or SD with no evidence of progression within 14 days prior to first dose of study treatment.\n\n  o Note: Patients must demonstrate at least stable disease (SD) or partial response (PR) by imaging. A single assessment showing PR at the end of chemotherapy (up to 32 weeks) is sufficient; confirmation is not required. If chemotherapy was discontinued between 16-32 weeks due to legitimate medical reasons (as determined by the investigator), the patient may still be eligible if they demonstrated SD or PR prior to discontinuation.\n* Have resolution of all chemotherapy-related toxicities to pre-treatment levels with exception of alopecia (which can be ongoing) and neuropathy (which can be ≤ Grade 2).\n* Eastern Cooperative Oncology (ECOG) performance status of 0 to 1.\n* Measurable disease per RECIST v1.1 (Section 17.2) is a requirement for study entry.\n* Willingness to undergo pre-treatment and on-treatment tumor biopsies. Tumor biopsies are mandatory for all patients with accessible disease, unless determined to be medically infeasible by the investigator.\n* Adequate organ function confirmed by the following laboratory values obtained ≤14 days prior to first administration of study treatment on Day 1:\n\n  * Absolute neutrophil count (ANC) ≥1.5 x 109\u002FL\n  * Platelets ≥100 x 109\u002FL\n  * Hemoglobin ≥9 g\u002FdL\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN); if liver metastases, then ≤5 x ULN\n  * Total bilirubin ≤1.5 x ULN; if liver metastases or metabolic disorder such as Gilbert's syndrome, then ≤2.5 x ULN\n  * Estimated glomerular filtration rate (GFR) (CLCr) ≥45 mL\u002Fmin using Cockcroft Gault formula\n* Females of childbearing potential \\[defined as a sexually mature woman who (1) has not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time during the preceding 24 consecutive months)\\] must:\n\n  * Have a negative serum or urine pregnancy test (β-human chorionic gonadotropin, β-hCG) as verified by the study investigator within 14 days prior to study treatment.\n  * Commit to complete abstinence from heterosexual contact or agree to use medical doctor-approved contraception throughout the study without interruption while receiving study treatment and for at least 120 days following last dose of study treatment.\n* Males must practice complete abstinence or agree to use a condom (even if he has undergone a successful vasectomy) during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 120 days following last dose of study treatment.\n\nExclusion Criteria:\n\n* Prior exposure to CD40 antibodies or any other immunomodulatory agent for the treatment of cancer\n* Prior exposure to odetiglucan\n* Received any systemic treatment for pancreatic adenocarcinoma within 14 days prior to the first dose of study therapy. For investigational agents, patients must not have had treatment within a time interval less than at least 5 half-lives of the investigational agent prior to the first scheduled day of dosing in this study\n* Had any active or inactive autoimmune disease or syndrome that required systemic treatment in the past 2 years, or currently requires systemic therapy with disease-modifying agents, corticosteroids, or immunosuppressive drugs. Examples include but are not limit to: rheumatoid arthritis, systemic sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g. Granulomatosis with polyangiitis, formerly Wegener's Granulomatosis), multiple sclerosis, inflammatory bowel disease, or motor neuropathies of autoimmune origin (e.g. Guillain-Barre Syndrome)\n\n  o Note: Patients are permitted to enroll if they have vitiligo or resolved childhood asthma\u002Fatopy, hypothyroidism stable on hormone replacement, controlled asthma, psoriasis not requiring systemic treatment, Type I diabetes, Graves' disease, or Hashimoto's disease, or with medical monitor approval.\n* An ongoing or active infection requiring intravenous antibiotics, antivirals, or antifungals during the 14 days prior to first dose of study drug\n* An uncontrolled concurrent illness, symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina, uncontrolled hypertension, or cardiac arrhythmia\n* History of (non-infectious) pneumonitis that required steroids, current pneumonitis, or a history of interstitial lung disease\n* QT interval corrected for heart rate using Fridericia's (QTcF) method \\>450 msec for males and \\>460 msec for females\n* A history of myocardial infarction within 6 months or a history of arterial thromboembolic event within 3 months of the first dose of investigational agent\n* A history of human immunodeficiency virus (HIV), hepatitis B (HB), or hepatitis C, except for the following:\n\n  * Patients with anti-HB core antibody but with undetectable HB virus deoxyribonucleic acid (DNA) and negative for HB surface antigen\n  * Patients with resolved or treated hepatitis C virus (HCV) (i.e. HCV antibody positive but undetectable HCV RNA)\n* Received concurrent or prior use of an immunosuppressive agent within 14 days of the first dose of investigational agent, with the following exceptions and notes:\n\n  * Systemic steroids at physiologic doses (equivalent to dose of 10 mg oral prednisone) are permitted\n  * Intranasal, inhaled, topical intra-articular, and ocular corticosteroids with minimal systemic absorption are permitted\n* Patients must not have known, symptomatic brain or leptomeningeal metastases\n* Major surgical procedure within 21 days prior to first dose of study drug. Non-study related minor surgical procedures requiring local\u002Fepidural anesthesia must be completed at least 72 hours before study drug administration. In all cases, patients must be sufficiently recovered and stable before treatment administration\n* Other malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancer; or any other cancer from which the patient has been disease-free for at least 3 years\n* Received a live vaccine within 28 days before the first dose of study drug. If enrolled, patients should not receive live vaccines during the study or for 28 days after the last dose of study treatment (Note: seasonal influenza vaccines for injection are generally inactivated and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines and are not allowed)\n* Females who are pregnant or lactating or who intend to become pregnant during participation in the study are not eligible to participate\n* Known alcohol or drug abuse\n* Any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent",{"count":504,"type":22},100,[89],"Phase II, open-label, single-arm study of CD40\u002FDectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.",[508],"Pancreatic Ductal Adenocarcinoma",{"date":423,"type":45},{"date":511,"type":45},"2025-11-25",{"date":513,"type":22},"2028-12",{"name":51,"class":52},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":529,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":143},"100597860","use-of-transcutaneous-electrical-nerve-stimulation-device-reletex-reliefband-with-current-eras-enhanced-recovery-after-surgery-protocol-to-further-decrease-postoperative-nausea-and-vomiting-in-the-bariatric-surgical-patient-within-the-first-24-hours-postoperatively-100597860","NCT07063979","Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.","Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband to Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient","Inclusion Criteria:\n\n* Adults 18-75 years of age\n* BMI 35 or greater\n* Patients eligible for and undergoing a Robotic Sleeve Gastrectomy\n* Able to consent on own behalf\n\nExclusion Criteria:\n\n* A diagnosis of gastroparesis\n* Pregnancy\n* Presence of a cardiac pacemaker\u002Fdefibrillator or intrathecal pump\n* Current smoker or tobacco use within 30 days of procedure.\n* Known allergic reactions to conductivity gel.\n\nDue to the nature of the Robotic Sleeve Gastrectomy patients who may be unable to follow or comprehend the long-term restrictions and\u002For requirements inherent of the surgery due to altered mentation are excluded from having the surgery.","75 Years",{"count":504,"type":22},[25],"The goal of this clinical trial is to learn if the Reletex Reliefband device when used in conjunction with our current treatments will further decrease postoperative nausea and vomiting. The Investigators want to test how well it works, specifically in bariatric surgery patients that are at a higher risk for nausea and vomiting after surgery. Furthermore, the investigators would like to see if using this non-drug treatment option might allow for the same or better control of nausea and vomiting with fewer side effects than the current medications used. This may decrease drowsiness, and allow for earlier mobility, increase comfort, and generally accelerate recovery after surgery.\n\nThe main questions it aims to answer are:\n\n* Does the use of Reletex Reliefband decrease postoperative nausea and vomiting (PONV) in the Bariatric surgical patient, therefore decreasing need for additional anti-emetics.\n* Does the use of Reletex Reliefband the use of the Reletex Reliefband during the immediate post-operative period reduce PONV, allowing for early mobility, decreased pain and length of stay (LOS).\n* Does the use of Reletex Reliefband decrease the use of medications for nausea and therefore decrease costs.\n* Does the use of Reletex Reliefband reduce prolonged PONV and therefore prevent the downstream effects, i.e. less mobility, increased pain, inhibit the patients' ability to comply with recommended treatments.\n* If reducing PONV using non-pharmaceutical approaches will improve outcomes and patient experiences.\n\nResearchers will compare to a placebo (a look-alike device) to see if the Reletex Reliefband works to decrease PONV.\n\nParticipants will:\n\n* All receive the standard Enhanced Recovery After Surgery (ERAS) Protocol before, during and after surgery. (This includes use of premedications for pain, and nausea)\n* Have a band applied and turned on at the completion of the patient's bariatric sleeve surgery. The band will be adjusted based on need and worn for a total of 24 hours postoperatively.\n* Have a pedometer clipped to their gown, to remain in place for 24 hours postoperatively\n* Be assessed regularly during their hospital stay by the nurses to monitor the site of the band, their level of nausea\u002Fvomiting, pain levels, and level of mobility",[527,528],"Postoperative Nausea and Vomiting","Bariatric Sleeve Gastrectomy",[530,531,532,533],"Prevention of Postoperative Nausea and Vomiting in Bariatric Patient","Reletex Reliefband to prevent PONV","Preventing PONV in Bariartic Postop patient","Reliefband",{"date":423,"type":45},{"date":536,"type":45},"2025-11-04",{"date":538,"type":22},"2027-07",{"name":51,"class":52},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":143},"100542341","improving-access-to-opioid-use-disorder-treatment-among-marginalized-patients-with-a-tailored-telehealth-intervention-100542341","NCT06341608","Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention","Aim 1:\n\nInclusion Criteria\n\nFor patients:\n\nMust be 18 years old or older\n\nClinical diagnosis of opioid use disorder and\u002For mental health diagnosis\n\nMust be receiving treatment for opioid use disorder and\u002For mental health diagnosis at an outpatient community-based substance use disorder and\u002For mental health treatment program\n\nMust speak English\n\nFor providers and staff:\n\nMust be 18 years old or older\n\nMust be in a provider, clinical staff, or leadership role caring for patients with substance use disorders and\u002For mental health diagnoses\n\nMust speak English\n\nAim 2b:\n\nInclusion Criteria:\n\nMust be 18 years or older\n\nClinical diagnosis of opioid use disorder\n\nMust be receiving treatment for OUD with buprenorphine at Prevention Point Philadelphia\n\nMust speak English\n\nAim 3:\n\nPatient participants:\n\nMust be 18 years old or older\n\nClinical diagnosis of opioid use disorder\n\nMust be currently receiving in-person disorder care with buprenorphine at Prevention Point for a duration of 1-3 months OR not currently receiving disorder treatment but approved for treatment intake at buprenorphine clinic by Prevention Point clinician\n\nMust be English speaking\n\nProvider and staff participants:\n\nMust be a provider or staff member at Prevention Point Philadelphia in the buprenorphine OUD treatment program\n\nMust be involved in the care of at least one patient enrolled in the pilot trial\n\nMust be English speaking",{"count":361,"type":22},[25],"The goal of this pilot trial is to develop and test a telehealth intervention for OUD care delivery and refine measurement strategies.\n\nThe specific aims are to: 1) identify components of an effective telehealth intervention and barriers to implementation, 2) partner with an advisory board of OUD treatment stakeholders from different settings to develop a telehealth intervention for OUD treatment with buprenorphine, and 3) conduct a pilot trial of the telehealth intervention for OUD treatment.\n\nThe investigators will enroll 60 patients, 30 individuals who are currently enrolled in in-person OUD treatment with buprenorphine, with a treatment episode duration of 1-3 months, and 30 individuals who are not currently receiving OUD treatment but approved for treatment intake at buprenorphine clinic by an OUD treatment clinician, to receive the telehealth for OUD care delivery intervention. The investigators will measure clinical, implementation, and patient satisfaction outcomes.",[550],"Opioid Use Disorder",{"date":395,"type":45},{"date":553,"type":22},"2026-09-15",{"date":555,"type":22},"2028-04",{"name":51,"class":52},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":564,"enrollmentInfo":565,"targetDuration":4,"studyType":23,"phases":567,"briefSummary":569,"conditions":570,"keywords":575,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":587,"leadSponsor":589,"locationsCount":143},"100634674","phase-4-a-smart-approach-to-evaluating-the-benefits-of-common-prescription-and-otc-medications-for-insomnia-100634674","NCT07542756","A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia","Sequential Multiple Assignment Randomized Trial Comparing Commonly Prescribed and Over the Counter Medications for the Treatment of Insomnia in Adults","Inclusion Criteria\n\n* Adults aged 18-80 years.\n* Meet DSM-5 criteria for Insomnia Disorder.\n* Score ≥15 on the Insomnia Severity Index (ISI).\n* Sleep initiation and\u002For maintenance complaints: ≥30 minutes in duration, occurring ≥3 nights\u002Fweek, with a duration of ≥3 months.\n* Willingness to discontinue use of all sleep-related medications prior to enrollment.\n* Completion of a 2-week washout period before starting any study medication.\n* Willingness to provide clinician assent for participation.\n\nExclusion Criteria\n\nPatients will be ineligible if they meet any of the following criteria: self-reported daytime napping (≥1 hour per day on ≥3 days per week); a history of suicidal attempts or current ideation, acute or chronic psychiatric or medical condition not controlled by therapy (according to their primary care physician), or current alcohol or drug misuse; or the diagnoses of (or high risk for) other sleep disorders, including circadian rhythm disorders (phase advance or phase delay syndromes), shift work related sleep disorder (\"day sleepers\" who work \\~11pm to 7am) and those with rotating shiftwork schedules. To determine eligibility, all subjects will be screened using a multitier process including: an online screener; an intake interview; a review of the subjects EMR; and, finally, the receipt of the patient's PCP's assent. The following provides additional listing and details (AD) for the Exclusion Criteria:\n\nGeneral Considerations\n\n* Age \\\u003C 18 or \\> 80 years old\n* Inadequate English language comprehension\n* Minimal facility with smartphones, computers, i-Pads, or the internet.\n\nWomen's Health Given the potential for teratogenic effects with at least trazodone (FDA Class C), women intending to become pregnant, or who are pregnant, or who are breastfeeding will not be eligible for the study. Women will be asked to confirm the use of birth control using self-report and, if applicable, by providing evidence of contraceptive medication (e.g., prescription or pill pack). We will perform a urine pregnancy test at baseline for female participants who are of reproductive age to confirm eligibility. At study enrollment, participants will be told to alert the study team and stop taking study medications if they become pregnant. Participants will be asked to test for pregnancy in the event of a missed cycle.\n\nMedical and Psychiatric Considerations\n\n* Acute or unstable psychiatric conditions\n* Unstable medical condition, significant medical disorder, or acute illness (as determined by their PCP), within one month prior to the study period.\n* Significant liver or kidney problems\n* Pheochromocytoma or porphyria (contraindicated for trazodone)\n* Epilepsy or Seizure Disorder (contraindicated for trazodone)\n* Glaucoma or urinary retention (contraindicated for doxepin)\n* Increased ocular pressure (contraindicated for diphenhydramine)\n* Diagnosis of alcohol or substance use disorder within 2 years prior to the screening visit\n* Inability to refrain from drinking alcohol or substance use for at least 3 consecutive days\n\nSleep Disorders and Sleep Habits\n\n* Any lifetime history of (diagnosis of) breathing disorders, including COPD and sleep apnea.\n* Shift work related sleep disorder (work \\~11pm to 7am and \"day sleeper\") and rotating shiftwork schedules\n* Circadian rhythm disorders (phase advance or phase delay syndromes)\n* Self-reported usual daytime napping ≥1 hour per day (3 or more days per week)\n\nMedications and Concomitant meds\n\n* Known hypersensitivity or contraindication to study drugs\n* Known hypersensitivity or contraindication to drugs of the same class as the study treatments\n* Known hypersensitivity or contraindication to any excipients of the study drug formulation\n* Treatment with CNS active drugs prohibited by the protocol for five half-lives of the respective drug (or 2 weeks)\n\nLifestyle\n\n* Heavy tobacco use (≥1 pack of cigarettes a day or inability to refrain from smoking during the night)\n* Not able or willing to stop treatment with moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors","80 Years",{"count":566,"type":22},1200,[568],"PHASE4","The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better risk\u002Fbenefit profile (doxepin).",[571,572,573,574],"Insomnia","Insomnia Disorder","Chronic Insomnia","Chronic Insomnia Disorder",[576,571,577,578,579,580,581,582],"Sleep","Zolpidem","Diphenhydramine","Doxepin","Melatonin","Trazodone","Placebo","2026-06-04",{"date":585,"type":45},"2026-06-05",{"date":187,"type":45},{"date":588,"type":22},"2032-01-01",{"name":51,"class":52},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":18,"minAge":223,"maxAge":597,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":77},"100575270","suicide-assessment-and-feasible-evidence-based-treatments-for-youth-living-with-hiv-in-lilongwe-100575270","NCT06770101","Suicide Assessment and Feasible Evidence-based Treatments for Youth Living With HIV in Lilongwe","Suicide Assessment and Feasible Evidence-based Treatments for Youth Living With HIV in Lilongwe: SAFETY Planning Pilot Trial","Inclusion Criteria:\n\n* Age 13-19\n* Diagnosed with HIV\n* Report current or historical suicidal ideation and behaviors (SIBs) on question 9 of the Patient Health Questionnaire modified for adolescents (PHQ-9-A) and the Ask Suicide-Screening questionnaire (ASQ)\n* Living in the clinic's catchment area with intention to remain for more than 1 year\n* Willing to provide consent (age 18+ or 16-17 years old and married and thereby considered emancipated minors per Malawi law) or assent with parental consent (age 13-17).\n\nExclusion Criteria:\n\n* Refuse to participate\n* Refuse to be audio-taped for in-depth interviews","19 Years",{"count":361,"type":22},[25],"The overall aim of this study is to determine the feasibility, fidelity, acceptability, and preliminary effectiveness of the Friendship Bench +Safety Planning intervention in reducing suicidal ideation and behaviors (SIBs) and improving HIV engagement amongst adolescents living with HIV (ALWH) when compared to augmented usual care.",[602,240],"HIV",[602,240,229],{"date":585,"type":45},{"date":606,"type":45},"2025-07-01",{"date":608,"type":22},"2026-09",{"name":51,"class":52},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":617,"enrollmentInfo":618,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":53},"100546239","evaluation-of-accelerated-sampling-techniques-for-vessel-wall-imaging-100546239","NCT06392347","Evaluation of Accelerated Sampling Techniques for Vessel Wall Imaging","Optimizing Scan Efficiency of T1-weighted (T1w) Imaging for Vessel Wall Imaging Protocols","Inclusion Criteria:\n\n1\\. Patients 18 years of age and scheduled to undergo clinical vessel wall MR imaging exams as part of their standard of care.\n\nExclusion Criteria:\n\n1. Any person under the age of 18\n2. Presence of artifact-producing intracranial devices (aneurysm clips\u002Fcoils, ventricular drains, craniectomy mesh, etc.)\n3. Any person with contraindications to MRI (medical instability, non-MRI compatible implanted devices, retained metallic foreign bodies, claustrophobia)\n4. Large space-occupying lesions (50 mL) or substantial mass effect (herniation, 5mm midline shift) on preceding brain imaging,\n5. Imminently life-threatening co-morbid conditions\n6. A history of premorbid disabling neurological or psychiatric disease, current substance abuse or remote substance abuse with permanent organic sequelae\n7. Pregnancy or lactation","99 Years",{"count":619,"type":22},15,"The purpose of this study is to compare and evaluate a faster MR image that has been optimized to look at participants blood vessel walls.",[622],"Vasculopathy",{"date":465,"type":45},{"date":625,"type":22},"2027-08",{"date":627,"type":22},"2030-07",{"name":51,"class":52},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":636,"targetDuration":4,"studyType":23,"phases":638,"briefSummary":639,"conditions":640,"keywords":642,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":649,"leadSponsor":651,"locationsCount":143},"100643396","colorectal-cancer-screening-preventive-reminder-ordering-assistance-via-texting-for-improved-visit-encounters-100643396","NCT07636174","Colorectal Cancer Screening Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters","CRC PROACTIVE","Inclusion Criteria:\n\nAll patients must meet the following criteria to be eligible:\n\n1. Age 18 years or older\n2. A scheduled new or return (non-urgent\u002Fsick) primary care visit at one of the study practices\n3. Overdue for colorectal cancer screening by health maintenance\n4. Ordered for FIT or Colonoscopy at the eligible visit\n\nExclusion Criteria:\n\nAs this trial is integrated with routine clinical operations, there will be no exclusion criteria other than already having an eligible visit at some point during the trial duration with an order for FIT or Colonoscopy.",{"count":637,"type":22},3888,[25],"Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. A substantial portion of the United States population remains overdue for screening, despite availability and insurance coverage of preventive health services. Barriers for completion and remaining up to date with screening include patients not remaining actively engaged with their care team, time constraints during office visits, and operational strain. This project aims to implement and evaluate a primary care visit-based outreach program that improves patient follow through on completion of overdue CRC screening.\n\nThis will be a 6 month, stepped-wedge, pragmatic trial conducted at Penn Medicine.",[641],"Behavior, Health",[643,644,645],"EHR Nudge","Behavioral Economics","Preventive Health","2026-06-03",{"date":395,"type":45},{"date":465,"type":22},{"date":650,"type":22},"2027-05-23",{"name":51,"class":52},""]